Generate:Biomedicines, the Flagship Pioneering-founded AI-enabled antibody company, filed for an IPO to fund late-stage development of engineered protein therapeutics including GB-0895 and GB-4362. The S-1 highlights AI-driven design aimed at accelerated candidate selection and extended half-life engineering for phase‑3-stage programs. Generate’s filing emphasizes a programmable-biology approach and existing partnerships with Amgen and Novartis, which underpin the company’s growth thesis. The company plans to use proceeds for phase 3 asthma trials and to advance CAR‑T and ADC-supporting programs. Investors will watch valuation, clinical milestones and the degree to which AI-originated assets deliver differentiated profiles in human studies. The filing adds momentum to a nascent biotech IPO cadence focused on AI-designed biologics.